STXS
AMEXStereotaxis Inc.
Stereotaxis Inc. (STXS) is a Biotechnology: Electromedical & Electrotherapeutic Apparatus company listed on AMEX. In the last 30 days Quantisnow tracked 7 wire items for STXS, including 4 press releases and news items, 2 earnings updates and 1 SEC filing. The most recent was published Nov 10, 2026.
STXS rankings
Financial highlights
Full financials- Revenue, TTM
- $30.07M
- Revenue growth
- -5.5%
- Net income, TTM
- -$22.32M
- Net margin
- -74.2%
- Free cash flow, TTM
- -$15.50M
- Cash
- $10.49M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks31+100%
2026-05-172026-11-08
Mix1390d
- SEC Filings5(38%)
- Other5(38%)
- Earnings2(15%)
- Leadership1(8%)
Activity · 52 weeks6137 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECStereotaxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Stereotaxis, Inc. (0001289340) (Filer)
- PRStereotaxis Reports 2026 Third Quarter Financial Results & Business UpdatesST. LOUIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the third quarter ended September 30, 2026. "Our near-term priority is to drive forward two major business model transformations," said David Fischel, Chairman and CEO. "The first is shifting from capital systems that require long sales and construction timelines, to having a portfolio of systems that are significantly more accessible and scalable. The second is developing and commercializing a portfolio of disposable interventional catheters that enhance the value
- PRStereotaxis Announces Convertible Note Financing of Up To $24 MillionST. LOUIS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for a convertible note financing of up to $24 million. "We appreciate the confidence and support from several of our long-term shareholders in this oversubscribed financing," said David Fischel, Chairman and CEO. "Our strengthened balance sheet positions us to execute our strategy and accelerate adoption of our comprehensive portfolio of innovations." The financing includes an initial upfront closing of $12 million, and an additional $12 mi
- PRFirst-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT100% clinical success and no device-related adverse events in 20 First-in-Human Percutaneous Coronary Intervention procedures with next-generation robotic systemRobocath system demonstrates ability to efficiently and effectively support the full range of coronary interventions including in complex coronary artery disease patientsPrincipal investigator, Dr. Nejjari, shared the findings during the "Innovations in Robotics for Transcatheter Heart Interventions" session at TCT on November 1, 2026 ST. LOUIS and ROUEN, France, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announ
- PRCanon Medical and Stereotaxis Collaborate to Advance Robotic ElectrophysiologyCollaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technologyTechnologies will be presented at TCT 2026 in the Canon booth TUSTIN, Calif. and ST. LOUIS, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Canon Medical Systems USA, a leader in innovative diagnostic imaging solutions, and Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced a technology compatibility and commercial collaboration to pair Canon Medical’s Alphenix interventional imaging platform with Stereotaxis’ GenesisX Robotic Magnetic Navigation system. Canon and Stereotaxis are collabo
- PRStereotaxis Announces First Robotic Magnetic Navigation System in LatviaPauls Stradiņš Clinical University Hospital installs Genesis Robotic Magnetic Navigation System, establishing the first robotic program for the treatment of cardiac arrhythmia in LatviaFirst procedures successfully treated patients with a broad range of arrhythmia ST. LOUIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Pauls Stradiņš Clinical University Hospital in Riga, Latvia, has established the first robotic center for the treatment of cardiac arrhythmias in Latvia and has successfully treated initial patients with the Genesis Robotic Magnetic Navigatio
- PRStereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026ST. LOUIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 third quarter on Tuesday, November 10, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments. What:Stereotaxis third quarter 2026 financial results conference callWhen: Tuesday, November 10, 2026, at 4:30 p.m. ET (1:30 p.m. PT)Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (In
- PRStereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026New digital technologies, including Synchrony and SynX, will be featured at HRXStereotaxis CEO to join main-stage panel on Autonomous EP Systems ST. LOUIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its portfolio of digital and robotic technologies will be featured at Heart Rhythm Society’s HRX conference, taking place September 18-20, 2026, in Atlanta, Georgia. Pioneered by the Heart Rhythm Society, HRX brings together clinicians, engineers, and entrepreneurs to explore advances in connectivity, artificial intelligence and automation in cardiovascular
- PRUniversity of Szeged Celebrates Strongest First Month of Robotic Cardiology ProgramUniversity of Szeged installed Hungary’s first Robotic Magnetic Navigation system in JulyOver 70 patients with all forms of arrhythmia treated robotically to date, a record pace of use globallyRobotics enabled successful treatment of patients with multiple previously failed ablation proceduresUniversity of Szeged to celebrate leadership in technology and grand opening of Robotic Cardiology Program at upcoming scientific symposium on September 8th ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the Electrophysiology team at the University of Szeged
- SECSEC Form EFFECT filed by Stereotaxis Inc.EFFECT - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form EFFECT filed by Stereotaxis Inc.EFFECT - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form 424B3 filed by Stereotaxis Inc.424B3 - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form 424B3 filed by Stereotaxis Inc.424B3 - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form 10-Q filed by Stereotaxis Inc.10-Q - Stereotaxis, Inc. (0001289340) (Filer)
- SECStereotaxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Stereotaxis, Inc. (0001289340) (Filer)
- PRStereotaxis Reports 2026 Second Quarter Financial Results & Business UpdatesRobotic catheter revenue surpasses $1M in the quarter, growing 270% sequentiallyFirst GenesisX robotic system purchase by US hospital to be installed this fallMultiple Synchrony digital operating room systems sold and installed following FDA clearance in AprilCompleted previously announced acquisition of Robocath, strengthening robotic technology leadership across the full spectrum of endovascular procedures ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30, 2026. "Stereotaxis
- PRMobia Medical Appoints Myriam Curet, M.D., to its Board of DirectorsAUSTIN, Texas, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (NASDAQ:MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Myriam Curet, M.D., to the Board as an independent director, effective July 30, 2026. "We are thrilled Myriam will be joining the Mobia Medical Board of Directors," said Richard Foust, President and Chief Executive Officer of Mobia Medical. "Her decades long clinical and executive leadership at Intuitive Surgical paired with her ongoing surgical practice and public company board experience bring a unique combination of medical and corporate gove
- PRStereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis second quarter 2026 financial results conference call When:Tuesday, August 11, 2026, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (In
- PRUniversity of Szeged Pioneers First Robotic Cardiology Program in HungaryFirst Robotic Magnetic Navigation system installed in HungaryUniversity of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using precision of robotics ST. LOUIS, July 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of the first advanced robotic cardiology program in Hungary at the University of Szeged in Szeged, Hungary. The Cardiology Center (Szent-Györgyi Albert Clinical Center) at the University of Szeged is the first hospital in Hungary to establish a heart rhythm progr
- SECStereotaxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form S-3 filed by Stereotaxis Inc.S-3 - Stereotaxis, Inc. (0001289340) (Filer)
- SECSEC Form S-3 filed by Stereotaxis Inc.S-3 - Stereotaxis, Inc. (0001289340) (Filer)
- SECStereotaxis Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Stereotaxis, Inc. (0001289340) (Filer)
- PRStereotaxis Completes Acquisition of RobocathST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previously announced acquisition of Robocath, an innovator of robotic technologies for interventional cardiology and neurointerventions. Robocath will now be fully integrated into Stereotaxis, combining complementary technologies and expertise to accelerate the development of next-generation robotic solutions for electrophysiology, interventional cardiology, and neurointerventions. The combined platform strengthens Stereotaxis’s position as the leader in robotic t
- INSIDERDirector Shamir Nachum was granted 43,103 shares, increasing direct ownership by 32% to 179,327 units (SEC Form 4)4 - Stereotaxis, Inc. (0001289340) (Issuer)
STXS FAQ
10 questionsWhat does Stereotaxis Inc. do?
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage...What is the latest news on STXS?
In the last 30 days Quantisnow tracked 7 wire items for STXS: 4 press releases and news items, 2 earnings updates and 1 SEC filing. The most recent was published on November 10, 2026.What is STXS revenue?
Stereotaxis Inc. (STXS) reported $30.07M of revenue for the twelve months ended Jun 30, 2026. That is down 5.5% from the year before. Revenue for fiscal 2025 was $32.38M.Is STXS profitable?
No. Stereotaxis Inc. reported a net loss of $22.32M for the twelve months ended Jun 30, 2026.How much cash and debt does STXS have?
Stereotaxis Inc. reported $10.49M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does STXS stock trade?
Stereotaxis Inc. (STXS) is listed on AMEX.What sector and industry is STXS in?
Stereotaxis Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about STXS?
Stereotaxis Inc. has had 6 recent analyst actions on file. The most recent action was from Citizens JMP: Mkt Outperform with a $4.00 price target on 2025-12-16. Recent price targets range from $4.00 to $13.00.What companies are similar to STXS?
Notable peers in the same industry include INMD (InMode Ltd.), AXGN (Axogen Inc.), TMDX (TransMedics Group Inc.), MDT (Medtronic plc.), LIVN (LivaNova PLC). Compare STXS side-by-side with any of them on Quantisnow.How can I track STXS on Quantisnow?
Quantisnow aggregates Stereotaxis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STXS to receive live email and push alerts on every new disclosure.